🔎 Trials Near Me

Akèy › Limfòm Burkitt › Ohio › Columbus

Etid klinik pou Limfòm Burkitt nan Columbus, OH

8 etid pou Limfòm Burkitt ap chèche patisipan nan sit nan ak bò kote Columbus (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.

Tèks ofisyèl etid la (Anglè)

Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

Ap rekriteFaz 3
  • Ohio State University Comprehensive Cancer Center, Columbus
Laj 18 a 39 · Tout sèks · Mizajou Oct 2, 2026 · NCT03150693

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

Ap rekriteFaz 2
  • Ohio State University Comprehensive Cancer Center, Columbus
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT03739814

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Ap rekriteFaz 2
  • Nationwide Children's Hospital, Columbus
Laj 1 a 30 · Tout sèks · Mizajou Sep 1, 2026 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Ap rekriteFaz 3
  • Nationwide Children's Hospital, Columbus
365 Days – 25 Years · Tout sèks · Mizajou Aug 25, 2026 · NCT03959085

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

Ap rekriteFaz 1/2
  • The Ohio State University Wexner Medical Center, Columbus
Laj 13 a 90 · Tout sèks · Mizajou Aug 6, 2026 · NCT06533579

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

Ap rekriteFaz 1
  • Nationwide Children's Hospital, Columbus
  • Ohio State University Comprehensive Cancer Center, Columbus
Laj 2 ak plis · Tout sèks · Mizajou May 29, 2026 · NCT05418088

Study of SGR-1505 in Mature B-Cell Neoplasms

Ap rekriteFaz 1
  • The Ohio State University - The James Cancer Hospital, Columbus
Laj 18 ak plis · Tout sèks · Mizajou Feb 13, 2026 · NCT05544019

Etid Limfòm Burkitt nan lòt vil

Lòt etid nan Columbus

Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.